These findings indicate that two doses of the neoAg-mRNA-LNP vaccine not only expanded T cells with neoAg-specific TCRs but also induced CD8+ T cells capable of recognizing MHC class I peptide complexes endogenously produced and presented by YTN16 cancer cells. The gene discussed is CD8A; the disease is cancer.